Endometrial Hyperplasia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Endometrial Hyperplasia is characterized by an abnormal proliferation of endometrial glands resulting from an imbalance between estrogenic stimulation and inadequate progesterone effects. This hormonal disarray can be triggered by various endogenous and exogenous factors, leading to irregular growth of the endometrium across a spectrum of changes. The risk factors associated with endometrial hyperplasia include age, nulliparity, obesity, genetic factors, diabetes mellitus, anovulatory cycles like in PCOS and perimenopause, ovarian tumors like granulosa cell tumors, hormone replacement therapy (especially estrogen-only therapy, which should be avoided in women with a uterus), over-the-counter herbal preparations with high estrogen content, as well as immunosuppression and infections, which might contribute to its development. Additionally, women with Hereditary nonpolyposis colorectal cancer or Lynch syndrome are at an increased risk of developing endometrial hyperplasia. The most common presentation of endometrial hyperplasia is abnormal uterine bleeding, manifesting as heavy menstrual bleeding (menorrhagia), irregular bleeding (metrorrhagia), unscheduled bleeding in patients on hormone replacement therapy, or postmenopausal bleeding. Abnormal discharge, such as foul-smelling or blood-stained, might also be observed. Diagnostic evaluations, including PAP smear, may reveal abnormal glandular or atypical endometrial cells, necessitating further investigation. Differential diagnoses for endometrial hyperplasia include conditions that cause focal or generalized thickening of the endometrium, such as endometrial cancer, endometrial polyps, and endometritis. Progestogens, which induce secretory changes in the endometrium, have shown promising results in regressing hyperplasia without atypia, but their efficacy is reduced in the presence of endometrial intraepithelial neoplasia.
Thelansis’s “Endometrial Hyperplasia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Endometrial Hyperplasia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Endometrial Hyperplasia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Endometrial Hyperplasia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment